Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

EWS/ETS-driven Ewing Sarcoma requires BET bromodomain proteins.

Gollavilli PN, Pawar A, Wilder-Romans K, Ramakrishnan N, Engelke CG, Dommeti VL, Krishnamurthy PM, Nallasivam A, Apel IJ, Xu T, Qin Z, Feng FY, Asangani IA.

Cancer Res. 2018 Jun 13. pii: canres.0484.2018. doi: 10.1158/0008-5472.CAN-18-0484. [Epub ahead of print]

PMID:
29898995
2.

Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer.

Speers C, Zhao SG, Chandler B, Liu M, Wilder-Romans K, Olsen E, Nyati S, Ritter C, Alluri PG, Kothari V, Hayes DF, Lawrence TS, Spratt DE, Wahl DR, Pierce LJ, Feng FY.

NPJ Breast Cancer. 2017 Aug 18;3:29. doi: 10.1038/s41523-017-0038-2. eCollection 2017.

3.

Glioblastoma Therapy Can Be Augmented by Targeting IDH1-Mediated NADPH Biosynthesis.

Wahl DR, Dresser J, Wilder-Romans K, Parsels JD, Zhao SG, Davis M, Zhao L, Kachman M, Wernisch S, Burant CF, Morgan MA, Feng FY, Speers C, Lyssiotis CA, Lawrence TS.

Cancer Res. 2017 Feb 15;77(4):960-970. doi: 10.1158/0008-5472.CAN-16-2008. Epub 2016 Dec 6.

4.

Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast Cancer.

Speers C, Zhao SG, Kothari V, Santola A, Liu M, Wilder-Romans K, Evans J, Batra N, Bartelink H, Hayes DF, Lawrence TS, Brown PH, Pierce LJ, Feng FY.

Clin Cancer Res. 2016 Dec 1;22(23):5864-5875. Epub 2016 May 25.

5.

The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression.

Niknafs YS, Han S, Ma T, Speers C, Zhang C, Wilder-Romans K, Iyer MK, Pitchiaya S, Malik R, Hosono Y, Prensner JR, Poliakov A, Singhal U, Xiao L, Kregel S, Siebenaler RF, Zhao SG, Uhl M, Gawronski A, Hayes DF, Pierce LJ, Cao X, Collins C, Backofen R, Sahinalp CS, Rae JM, Chinnaiyan AM, Feng FY.

Nat Commun. 2016 Sep 26;7:12791. doi: 10.1038/ncomms12791.

6.

Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer.

Qiao Y, Feng FY, Wang Y, Cao X, Han S, Wilder-Romans K, Navone NM, Logothetis C, Taichman RS, Keller ET, Palapattu GS, Alva AS, Smith DC, Tomlins SA, Chinnaiyan AM, Morgan TM.

Neoplasia. 2016 Jan;18(1):1-9. doi: 10.1016/j.neo.2015.11.009.

7.

BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer.

Asangani IA, Wilder-Romans K, Dommeti VL, Krishnamurthy PM, Apel IJ, Escara-Wilke J, Plymate SR, Navone NM, Wang S, Feng FY, Chinnaiyan AM.

Mol Cancer Res. 2016 Apr;14(4):324-31. doi: 10.1158/1541-7786.MCR-15-0472. Epub 2016 Jan 20.

8.

Development and validation of a novel platform-independent metastasis signature in human breast cancer.

Zhao SG, Shilkrut M, Speers C, Liu M, Wilder-Romans K, Lawrence TS, Pierce LJ, Feng FY.

PLoS One. 2015 May 14;10(5):e0126631. doi: 10.1371/journal.pone.0126631. eCollection 2015.

9.

Targeted radiosensitization with PARP1 inhibition: optimization of therapy and identification of biomarkers of response in breast cancer.

Feng FY, Speers C, Liu M, Jackson WC, Moon D, Rinkinen J, Wilder-Romans K, Jagsi R, Pierce LJ.

Breast Cancer Res Treat. 2014 Aug;147(1):81-94. doi: 10.1007/s10549-014-3085-5. Epub 2014 Aug 8.

PMID:
25104443
10.

Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer.

Asangani IA, Dommeti VL, Wang X, Malik R, Cieslik M, Yang R, Escara-Wilke J, Wilder-Romans K, Dhanireddy S, Engelke C, Iyer MK, Jing X, Wu YM, Cao X, Qin ZS, Wang S, Feng FY, Chinnaiyan AM.

Nature. 2014 Jun 12;510(7504):278-82. doi: 10.1038/nature13229. Epub 2014 Apr 23.

11.

PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer.

Prensner JR, Chen W, Iyer MK, Cao Q, Ma T, Han S, Sahu A, Malik R, Wilder-Romans K, Navone N, Logothetis CJ, Araujo JC, Pisters LL, Tewari AK, Canman CE, Knudsen KE, Kitabayashi N, Rubin MA, Demichelis F, Lawrence TS, Chinnaiyan AM, Feng FY.

Cancer Res. 2014 Mar 15;74(6):1651-60. doi: 10.1158/0008-5472.CAN-13-3159. Epub 2014 Jan 28.

12.

Targeted radiosensitization of ETS fusion-positive prostate cancer through PARP1 inhibition.

Han S, Brenner JC, Sabolch A, Jackson W, Speers C, Wilder-Romans K, Knudsen KE, Lawrence TS, Chinnaiyan AM, Feng FY.

Neoplasia. 2013 Oct;15(10):1207-17.

13.

Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes.

Augello MA, Burd CJ, Birbe R, McNair C, Ertel A, Magee MS, Frigo DE, Wilder-Romans K, Shilkrut M, Han S, Jernigan DL, Dean JL, Fatatis A, McDonnell DP, Visakorpi T, Feng FY, Knudsen KE.

J Clin Invest. 2013 Jan;123(1):493-508. doi: 10.1172/JCI64750. Epub 2012 Dec 21.

14.

Role of α(5)β(1) Integrin Up-regulation in Radiation-Induced Invasion by Human Pancreatic Cancer Cells.

Yao H, Zeng ZZ, Fay KS, Veine DM, Staszewski ED, Morgan M, Wilder-Romans K, Williams TM, Spalding AC, Ben-Josef E, Livant DL.

Transl Oncol. 2011 Oct;4(5):282-92. Epub 2011 Oct 1.

15.

Radiotherapy combined with intratumoral dendritic cell vaccination enhances the therapeutic efficacy of adoptive T-cell transfer.

Teitz-Tennenbaum S, Li Q, Davis MA, Wilder-Romans K, Hoff J, Li M, Chang AE.

J Immunother. 2009 Jul-Aug;32(6):602-12. doi: 10.1097/CJI.0b013e3181a95165.

16.

Enzastaurin, an inhibitor of PKCbeta, Enhances Antiangiogenic Effects and Cytotoxicity of Radiation against Endothelial Cells.

Spalding AC, Zeitlin BD, Wilder-Romans K, Davis ME, Nor JE, Lawrence TS, Ben-Josef E.

Transl Oncol. 2008 Dec;1(4):195-201.

Supplemental Content

Loading ...
Support Center